

Prevalence of Pulmonary Arterial Hypertension among Children with Rheumatic Heart Disease Attending Follow up at the Cardiac Clinic of Jimma University Medical Center

Yirga Y*

College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia

*Corresponding author: Yirga Y, Lecturer, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia, Tel: + 251913207208; E-mail: yenelink77@gmail.com

Received: April 22, 2019; Accepted: May 28, 2019; Published: June 04, 2019

Copyright: © 2019 Yirga Y. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Acute rheumatic fever and its chronic sequelae remain significant cause of morbidity and mortality in Ethiopia. Pulmonary hypertension is a frequent complication of left heart disease arising from a wide range of cardiac disorders. Epidemiological data are scarce, especially in the pediatric population of developing countries, regarding the prevalence of pulmonary hypertension among patients with rheumatic heart disease.

Objective: To determine prevalence of pulmonary arterial hypertension and associated factors among patients with rheumatic heart disease in Jimma university medical center.

Method: A cross sectional study was conducted by including patients who were 18 years and less and had been diagnosed with rheumatic heart disease and have Echocardiography report from January 2014 to August 2017. Their medical record was reviewed to retrieve relevant data to answer the study objectives. Data was entered and analyzed using SPSS for windows version 20. Descriptive statistics of categorical variables will be presented by frequencies and percentage and mean, and standard deviations will be estimated for continuous variables. Chi square test was performed to identify association between independent variables and pulmonary arterial hypertension.

Results: A total of 247 medical record of children with rheumatic heart disease were reviewed. Pulmonary hypertension occurred in 149 (60.3%) of the children with a mean age at 10.73 ± 2.837 years. Majority of the children were from rural area 99 (66.4%) and 88 (59.1%) were females. The average Tricuspid valve pressure gradient was 51.17 ± 18.67 mmHg. Heart failure was the presenting illness in 103 (69.1%) of children with PAH, having a significant association ($p \leq 0.001$). All associated comorbidities were more prevalent among those who have PAH, malnutrition being the commonest followed by pneumonia. Mitral valve was the most commonly involved valve alone or combined with aortic valve. Mixed Mitral and Aortic valve involvement was seen in 93 (62.4%) cases. Severity of Mitral Regurgitation, Mitral Stenosis and Aortic Regurgitation was found to have statistically significant association with $p \leq 0.05$. Medications were almost the only treatment modality, given to 147 (98.6%) children and a single child got a surgical repair.

Conclusion and Recommendations: Rheumatic heart disease related pulmonary hypertension is still the major problem in the center and mitral valve is the commonest valve to be affected. Children with heart failure at presentation are at increased risk of having pulmonary hypertension. Only one patient was operated for underlying valvular lesion. Introduction of standard treatment practices and further study to assess the reasons for late presentation of children with rheumatic heart disease before the development of pulmonary hypertension is recommended.

Keywords: Rheumatic heart disease; Pulmonary hypertension

Abbreviations: ARF: Acute Rheumatic Fever; AR: Aortic Regurgitation; AS: Aortic Stenosis; CCBs: Calcium Channel Blockers; CHF: Congestive Heart Failure; ECG: Electrocardiography; JUMC: Jimma University Medical Center; LVH: Left Ventricular Hypertrophy; MR: Mitral Regurgitation; MS: Mitral stenosis; NHYA: New York Heart Association; PA: Pulmonary Artery; PAH: Pulmonary Arterial Hypertension; PDEIS: Phosphodiesterase Inhibitors; PH: Pulmonary Hypertension; PVR: Pulmonary Vascular Resistance; RHD: Rheumatic Heart Disease; RVH: Right Ventricular Hypertrophy; TR: Tricuspid Regurgitation; WHO: World Health Organisation

Introduction

Pediatric pulmonary hypertension (PH) (pulmonary hypertension is pulmonary arterial pressure ≥ 25 mmHg which is measured indirectly by tricuspid regurgitation pressure gradient through transthoracic echocardiography) is high blood pressure in the arteries of the lungs (the pulmonary arteries). PH is a progressive disease where the pulmonary arteries continue to shrink, making the right side of the heart work harder as it makes the higher pressure needed to force blood through the narrowed arteries [1]. In severe cases of pediatric PH, the small blood vessels in the lungs are damaged to the point they are lost. This happens because the muscle in the arteries

contracts (vasoconstriction) and the artery muscle cells divide and plug up the arteries (muscle cell proliferation). The vessels can also become blocked with blood clots or the lungs can become damaged by illness. This causes the loss of air spaces and blood vessels in the lungs. PH may cause the right side of child's heart to become enlarged and eventually can cause right heart failure [2]. Pulmonary hypertension (PH) is a rare disease that can present in newborns, infants, and children and is associated with considerable morbidity and mortality. The etiology and presentation of PH varies substantially between children and adults. Unfortunately, the lack of sufficient controlled studies in children makes PH management challenging, with most therapeutic strategies based on extrapolation from adult studies and expert consensus [3]. Pulmonary hypertension (PH) is a frequent complication of left heart disease arising from a wide range of cardiac disorders. In the clinical classification, PH associated with left heart disease is classified as Group 2, which includes left heart systolic dysfunction, left heart diastolic dysfunction and left heart valvular disease. Rheumatic mitral valve disease is the most common cause of PH in left heart disease, particularly in pediatric patients [4,5].

Statement of the problem

As the incidence of these conditions is increasing, the number of patients presenting with PH is also increasing and today, left heart disease represents the most frequent cause of PH. The development of PH in patients with left heart disease is associated with poor prognosis. However, despite the increasingly large number of patients affected and the impact of PH on outcome, there are currently no specific treatment options for these patients [6]. Pulmonary hypertension constitutes a major burden in sub-Saharan Africa. Beside forms of PH prevalent elsewhere there are several risk factors affecting particularly children in this continent, namely: Untreated Congenital Heart Disease, Rheumatic Heart Disease, Endomyocardial Fibrosis, Infections: HIV/AIDS, Tuberculosis, Schistosomiasis, Sickle Cell Disease, Passive Indoor Smoking & Traditional Medication [7].

In sub-Saharan Africa the prevalence of RHD is high due to different factors. This fact is true for Ethiopia, where RHD constitute majority of the acquired heart disease in pediatric patients. Even though, there are no studies, it is estimated that PAH related to RHD occurs frequently in such patients and is one of the major causes of morbidity and mortality among those children. Due to difficulties in diagnosing PAH, the burden of it among pediatric patients with RHD is undermined in these areas. In Ethiopia, as part of sub-Saharan Africa, this fact is true. According to different studies the prevalence of RHD is estimated to range from 49.4 - 59.4% [8,9]. Unlike that of developed countries where PH is mainly caused by CHD, it is believed that RHD is the primary cause of PH.

Significant of the study

Since there is scarcity of available data, the aim of this study is to determine the prevalence of PAH, associated comorbidities and treatment practices in pediatric patients with RHD at JUMC and finally forwards some recommendation for its prevention and better treatment. In addition, this study will serve as a base for future studies to be conducted on pediatric pulmonary hypertension around the country.

Literature Review

Pediatric pulmonary hypertension is a relatively rare, often rapidly progressive disease with varied etiologies that is associated with significant morbidity and mortality. In fact, until recently, virtually all patients with this condition died within a few years of diagnosis. The incidence and prevalence of PAH were estimated to be 2.4-7.6 cases/million/year and 15-26 cases/million, respectively, in large population studies. Worldwide prevalence is hard to appraise, but it is surely underdiagnosed [10]. Though epidemiological data are scarce on the prevalence of PH in pediatric patients with RHD, it remains a major cause of morbidity and mortality. According to the journal of American college of cardiology the yearly incidence rate for PH were 63.7 per million children [11]. There are no enough data on the prevalence or incidence of PAH associated with RHD in Africa. Some studies estimate a higher prevalence of PAH in those pediatric patients having RHD. In a prospective, multinational cohort done in 4 African countries 11 pediatric cases with an age range of 1 to 17 years (8 females) captured by the registry [12]. The pharmacological management with different causes of PAH was reviewed in that study. Overall, loop diuretics were most commonly prescribed (89% of all cases). Alternatively, none of the cohort patients received home oxygen. Only a small proportion received advanced therapy such as a Phosphodiesterase-type-5 inhibitor (3%) [12].

The disease is more severe and malignant in sub-Saharan Africa for reasons that are unclear, causing early mitral and/or aortic disease that leads to pulmonary hypertension if untreated. In Cameroun secondary PH occurs in 20% of patients, In Kenya PH is the most common complication of mitral disease, PH is present in 20% of newly diagnosed RHD in South Africa, Severe PH in 61% of patients submitted to surgery in Mozambique [7,13,14]. The research done in Uganda have found PH in 291 (77.4%) of the 376 studied patients measured indirectly by TR pressure gradient ≥ 30 mmHg in the absence of RV outflow tract obstruction [15]. In a prospective registry which enrolled 3343 patients (median age 28 years, 66.2% female) presenting with RHD at 25 hospitals in 12 African countries (including Ethiopia), India, and Yemen between January 2010 and November 2012, the prevalence of PAH was 28.8% [16]. According to the study done in Jimma, Ethiopia, in which 254 children were included in five years retrospective analysis, the prevalence of RHD accounts for 74.1% of the acquired heart diseases. In this study the prevalence of PH was studied as a separate entity and constitute 3.4% of the acquired heart disease [17]. However, there is no proper documentation in Ethiopia regarding the prevalence of PH associated with RHD.

Objective

General objective

To determine prevalence and associated factors of patients with RHD among pediatric patients who have follow up at cardiac clinic at JUMC from January 2014 to August 2017.

Specific objectives

- 1) To determine prevalence of PAH in pediatric patients with RHD having follow up at JUMC
- 2) To determine factors associated with PAH in pediatric patients with RHD having follow up at JUMC

3) To assess treatment practices of PAH in pediatric patients with RHD having follow up at JUMC

Research Methodology

Study area

This study will be conducted in JUMC pediatric department. JUMC is the only referral hospital in south west and gives service for more than 12 million inhabitants of south west Ethiopia. The center has 4 major departments and other minor departments. The department of pediatrics and child health is one of the major departments, and it provides in-patient and out-patient services. The pediatric follow up clinics are amongst the out-patient services, one of this being pediatric cardiac clinic, which provides services on a regular weekly follow up basis.

Study period

The study was conducted from 25th September to 06th October 2017.

Study design

A cross sectional design was employed.

Population

Source population: All pediatric patients who have RHD and having at least one follow-up at the pediatric cardiac clinic of JUMC from January 2014 to August 2017.

Study population: All children with echocardiography proven cardiac valve lesion secondary to rheumatic heart disease during January 2014 to August 2017.

Sample size and techniques

In determining the sample size particular attention was given to getting adequate sample size that would ensure the generalization of the study findings. To affect this, the following assumptions and a standard sample size calculation formula are used to determine the number of RHD cases to be reviewed for the study.

Assumption

A relevant variable to the study under consideration i.e. the prevalence of PAH in RHD from a similar hospital-based study X% or no similar study is identified, but study in some Africa was taken as base line, then p is 77%. Margin of error (d) = 0.05, with 95% confidence level

$$N = \frac{Z^2 \cdot P(1-P)}{d^2}$$

Taking p=0.77 from previous studies in sub-Saharan region of the prevalence of PAH-RHD [15]. Confidence level (CI) = 95%

$$N = \frac{1.96^2 \times 0.77(1-0.77)}{0.05^2}$$

$$N = 272$$

Sampling methods not used and all records of children with RHD, who were seen during the above time period, medical record number was retrieved from logbook.

Measurement

Variables

Dependent variables: Prevalence of PAH

Independent variables: Age, Sex, Residency, Heart Failure at presentation, Type/s of valve lesion, Comorbid illnesses, Secondary prophylaxis, Echocardiography, Treatment practice

Data collection

Data was collected by using a pretested checklist which was prepared by principal Investigator. All relevant data were collected by chart reviewing and all answers were recorded.

Data analysis

A pretested checklist was used to extract the data and once completeness is checked, it was entered and analyzed using SPSS for windows version 20. Descriptive statistics of categorical variables is presented by frequencies and percentage and mean, and standard deviations will be estimated for continuous variables. Chi square test were performed to identify association between independent variables and pulmonary arterial hypertension.

Results

A total of 280 medical records were approached in the study, of whom 33 were excluded (15 cases had not started follow up, 11 has no echocardiography report and 7 cases had an alternative diagnosis). Medical records of 247 children's (41.7% male and 58.3% female) were reviewed thoroughly. 92 (37.2%) were in the age range of 5 to 9 years, while children in the age range of 10 to 14 years were 136 (55.1%) and those 15 years and above were 19 (7.7%). The average age of children at first follow up was 10.48 ± 2.98 years. 168 (68%) of the children came from rural area while the rest 32% were from urban areas. Mitral valve involvement was seen in almost all cases of the children, accounting 99.5%, followed by combination of mitral and aortic valve involvement 150 (60.7%).

Variables		PAH-RHD		
		RHD	Count	Percentage
Sex	Male	103	61	59.2
	Female	144	88	61.1
Residency	Urban	79	50	63.3
	Rural	168	99	58.9

Table 1: Sex distribution and residency of pediatric patients with PAH-RHD on follow up at JUMC cardiac clinic, July 2017, Jimma, Oromia, Ethiopia.

Mitral regurgitation was the most common lesion seen in 234 (94.7%), then aortic regurgitation 150 (60.7%), mitral stenosis 67 (27.1%), aortic stenosis was seen in only 5 (2.0%) of the children.

Pulmonary hypertension associated with rheumatic heart disease occurred in 149 (60.3%) of the children on follow up. Among those who developed PAH 86 (57.7%) had mild PH and the rest 63 (42.3%) was found to had severe PH. 88 (59.1%) of the children who had PH were females and 99 (66.4%) were from rural areas. The average TR pressure gradient among those who developed PH was 51.17 ± 18.67 mmHg (Table 1).

The average age at the diagnosis of PH was 10.73 ± 2.837 years. Of those who developed PAH children aged 5-9 years were 46 and account for 30.8%, 10-14 years 94 (63.1%) and those 15 and above were 9 (6.1%). Among children who are aged 5-9 years 50% developed PAH and 69.1% of children aged 10-14 years developed PAH; this was found to be statistically significant ($p=0.007$) (Figure 1 and Table 2).




Figure 1: Age distribution of pediatric patients with PAH - RHD on follow up at JUMC cardiac clinic, July 2017, Jimma, Oromia, Ethiopia.

Variables	Pulmonary Hypertension					Chi square value	p value
		Absent		Present			
		Count	%	Count	%		
Age (years)	5-9	46	50.00	46	50.00	9.844	0.007
	10-14	42	30.90	94	69.10		
	15-18	10	52.60	9	47.40		
Sex	Male	42	40.80	61	59.20	0.089	0.765
	Female	56	38.90	88	61.10		
Residency	Urban	29	36.70	50	62.30	0.427	0.513
	Rural	69	41.10	99	58.90		

Table 2: Frequency distribution of age, sex and residency among pediatric patients with PAH - RHD on follow up at JUMC cardiac clinic, July 2017, Jimma, Oromia, Ethiopia.

Heart failure was the presenting illness in most of the children having PAH than those without PAH. 103 of 149 children has heart failure at the time of presentation, accounting 69.1%. Among those

children with severe PAH, 45 (71.4%) had heart failure at time of presentation. However, this was seen in only 23 children (23.5%) who had not PAH. And there is a statically significant association between PAH and HF at first time of presentation to the hospital ($p<0.001$) (Table 3).

Variables		Pulmonary Hypertension				Chi-squar e result	p value
		Not present		Present			
		Count	%	Count	%	49.316	<0.001
Heart failure at presentation	Yes	23	23.5	103	69.1		
	No	75	76.5	46	30.9		
Total		98	100	149	100		

Table 3: Frequency of heart failure at the time of presentation in pediatric patients with PAH - RHD on follow up at JUMC cardiac clinic, July 2017, Jimma, Oromia, Ethiopia.

All (100%) patients was taking Byzantine penicillin G as a secondary prophylaxis, on monthly base. Despite this there were a total of 45(18.2%) rheumatic recurrence cases from the study population and among this 32 (71.1% of all the rheumatic recurrences) was seen in those children having PAH. All associated comorbidities were more prevalent in children with PAH than those without PAH. Malnutrition 39 (26.2%) being the commonest associated illness, followed by pneumonia 22 (4.8%) and rheumatic recurrence 14 (9.4%) as a single entity. 34 (22.8%) of children had more than one comorbidity at a time or in separate times. And only 24 (16.1%) of the children with PAH - RHD were found to have no associated illness (Figure 2).




Figure 2: Comorbid conditions in pediatric patients with PAH - RHD on follow up at JUMC cardiac clinic, July 2017, Jimma, Oromia, Ethiopia.

Mitral regurgitation was the most common valve lesion associated with PAH as an isolated or mixed involvement. Mixed Mitral and Aortic valve involvement was seen in 93 (62.4%) of children, there were 137 (91.9%) cases of MR among those who developed PAH. 32.8% of children with mild MR developed PAH, while 80.6% of children with severe MR developed PAH, and this was found to be statistically significant ($p \leq 0.001$). Aortic regurgitation was evident in

96 (64.4%) of children with PAH. 52.4% among Mild AR, 80% among Moderate AR and 78% among severe AR had PAH and there was significant association between the severity of AR and the prevalence of PAH ($p=0.01$). Severity of aortic regurgitation has a significant association with the presence of PAH ($p=0.001$). Mitral stenosis was found in 59 (39.5%) of children with PAH. Of those children with Mild MS 56.2%, Moderate MS 90.9 and all with Severe MS has developed PAH and this was also statistically significant ($p \leq 0.001$) (Table 4).

Valve lesions		Pulmonary Hypertension				Chi-squar e result	p- value
		Absent		Present			
		Count	Percenta ge	Count	Percent age		
Mitral Regurgit ation	Mild	41	67.20%	20	32.80%	67.306	<0.001
	Moderate	31	70.50%	13	29.50%		
	Severe	25	19.40%	104	80.60%		
	No	1	7.70%	12	92.30%		
Mitral stenosis	Mild	7	43.80%	9	56.20%	53.643	<0.001
	Moderate	1	9.10%	10	90.90%		
	Severe	0	0.00%	40	100.00%		
	No	90	50.00%	90	50.00%		
Aortic Regurgit ation	Mild	40	47.60%	44	52.40%	15.564	0.01
	Moderate	5	19.70%	20	80.30%		
	Severe	9	22.00%	32	78.00%		
	No	44	45.90%	53	54.10%		
Aortic stenosis	Mild	2	50.00%	2	50.00%	1.797	0.441
	Moderate	1	100.00%	0	0.00%		
	Severe	0	0.00%	0	0.00%		
	No	95	39.30%	147	60.70%		

Table 4: Echocardiography findings in pediatric patients with PAH - RHD on follow up at JUMC cardiac clinic, July 2017, Jimma, Oromia, Ethiopia.

Most patients were getting diuretics mainly Furosemide as a single or combined with other drugs. 142 (95.3%) of those children who had PAH was given diuretics alone or combined with other medications. 71 (47.6%) of the patients was given diuretics combined with ACEIs (mostly Captopril and few gets Enalapril). Anti-inflammatory medications (either ASA or Prednisolone or both) were also given for patients who developed rheumatic recurrence while on follow up. Among those children who developed PAH only 1 was not given medication, as compared to 36 (36.7%) of children without PAH. There was only 1 patient who had undergone surgery (Mitral Valve balloon Valvoplasty) for Severe MS, and he had a significant reduction in the TV Pressure gradient, 31 and 8 mmHg before and after the surgery, respectively (Figure 3).

Discussion

There is general scarcity of published data related to childhood RHD in the African countries that are most affected by the disease. This study aimed to describe prevalence, associated comorbidity and treatment of PAH among children with RHD and to explore the relationship between the severity of valvular dysfunction, age and heart failure at presentation with PAH. PAH was prevalent in 149 (60.3%) of children, where 63 (42.3%) had severe PAH, with mean age of 10.73 ± 2.837 years and female predominance (59.1%). This is comparable with the research among children done in Uganda, 291 (77.4%) of the 376 children studied with mean age of the children was 11.0 ± 2.7 years [15]. The study done in 14 developing countries among children and adults show 28.8% of prevalence, which may be due to the difference in the study population and the treatment given in earlier ages [16]. Other study done among adults and in Southern Yemen show the prevalence to be 80.4%, which may be due to a late presentation to medical attention, mean age was 28.6 ± 14.5 years [18]. Female predominance was also seen in all of the literatures [15-18]. The prevalence of PAH is affected by the age of the children at presentation when corrective treatment is not done, and the study showed this association with p value of 0.007.




Figure 3: Treatment practice in pediatric patients with PAH - RHD on follow up at JUMC cardiac clinic, July 2017, Jimma, Oromia, Ethiopia.

Most of the children, 103 (69.1%) had heart failure at presentation. Even if there is no data on the prevalence of heart failure among children with PAH - RHD, this finding is relatively higher from that of the study done in low income sub-Saharan African countries (children and adults who had RHD) showing 43.0% prevalence [16], the difference can be due to the late presentation in the first group. The presence of PAH is associated with heart failure at presentation ($p<0.001$). Mitral valve was the most commonly involved valve 100% alone or combined with aortic valve, Mixed Mitral and Aortic valve involvement was seen in 93 (62.4%) cases. Similarly, in the Uganda study of children with RHD, all except one of the 376 cases studied had mitral valve disease (MR or MS). Severity of Mitral Regurgitation, Mitral Stenosis and Aortic Regurgitation was found to have statistically significant association with $p \leq 0.05$.

Medications were almost the only treatment modality, given to 147 (98.6%) children and a single child got a surgical repair. This is very low as compared with 34.8% operation in patients with RHD (children

and adults) in Southern Yemen [18]. This difference can be due to the absence of surgical intervention all over the country, until a very recent time. According to the standard treatment guidelines for patients with RHD, which is surgical management of the involved heart valve either by repair or prosthetic replacement, the practice in the study population was found to be almost absent.

Generally, the study has identified the higher prevalence of PAH among children with RHD, which make them more susceptible to acquire heart failure and associated comorbidities. The involvement of heart valves is similar with what is known from studies done previously and severity can greatly affect the presence of PAH. However, the practice of the definitive management for children with RHD is poor and needs a better attention to prevent the occurrence of PAH.

Limitation of the Study

The biggest limitation of this study was the retrospective design - this is inevitably complicated by some incomplete data and lost records. The absence of previously published literature on the topic makes it difficult to compare and discuss some of the results.

Conclusion and Recommendations

Rheumatic heart disease related pulmonary hypertension is still the major problem in the center and mitral valve is the commonest valve to be affected. Age is one of the determining factors of development of PAH among children with RHD, as that of severity of heart valve lesion. Children with heart failure at presentation are at increased risk of having pulmonary hypertension. Only one patient was operated for underlying valvular lesion. Further study is needed to assess the reason for late presentation and the difficulty towards the standard treatment practices for children with rheumatic heart disease before the development of pulmonary hypertension.

Ethical Considerations

Prior to data collection official letter was written from Jimma University students research program to the card record office of JUMC. After getting permission data collection was started and patient confidentiality were kept throughout the study.

Conflicts of Interest

There are no conflicts of interest for the present study.

References

1. Humbet M (2015) Global alliance against chronic respiratory disease, pulmonary hypertension.
2. Kliegman RM, Gerber MA, Stanton BF, Schor NF, Richard E, et al. (2016) Behrman and rheumatic fever. In: Nelson textbook of pediatrics (20th edn). Philadelphia: Elsevier Saunders, USA. pp: 2269-2275.
3. Ivy DD, Abman SH, Barst RJ, Berger RM, Bonnet D, et al. (2013) Pediatric pulmonary hypertension. *J Am Coll Cardiol* 62: 117-26.
4. Guazzi M, Galie N (2012) Pulmonary hypertension in left heart disease. *Eur Respir Rev* 21: 338-346.
5. Rubin LJ, Hopkins W (2013) Overview of pulmonary hypertension in adults, Up to Date 21.2 clinical reference.
6. Hawkins A, Tulloh R (2009) Treatment of pediatric Pulmonary Hypertension. *Vasc Health Risk Manag* 5: 509-524.
7. Mocumbi AO (2011) Pulmonary hypertension in sub Saharan Africa, unique diagnosis, challenge and solution. 4th international conference on neonatal and childhood pulmonary vascular disease.
8. Dejuma Y, Girma T, Girmaye A, Asfawossen B (2005) Rheumatic fever and rheumatic heart disease for the ethiopian health center team. Ethiopian Public Health Training Initiative.
9. Daniel E, Abegaz B, Muhe L (1990) Profile of cardiac disease in Ethiopian children, *East Afr Med J* 67: 113-117.
10. Lourenço AP, Fontoura D, Henriques-Coelho T, Leite-Moreira AF (2012) Current pathophysiological concepts and management of pulmonary hypertension. *Int J Cardiol* 155: 350-361.
11. Sitbon O, Humbert M, Jaïs X, Iosos V, Hamid AM, et al. (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation* 111: 3105-3111.
12. Thienemann F, Dzudie A, Mocumbi AO, Blauwet L, Sani MU, et al. (2016) The causes, treatment, and outcome of pulmonary hypertension in Africa: Insights from the Pan African Pulmonary Hypertension Cohort (PAPUCO) Registry. *Int J Cardiol* 221: 205-211.
13. Sadiq M, Islam K, Abid R, Latif F, Rehman AU, et al. (2009) Prevalence of rheumatic heart disease in school children of urban Lahore. *Heart* 95: 353-357.
14. Marijon E, Ou P, Celermajer DS, Ferreira B, Mocumbi AO, et al. (2007) Prevalence of rheumatic heart disease detected by echocardiographic screening. *N Engl J Med* 357: 470-476.
15. Lubega S, Aliku T, Lwabi P (2014) Echocardiographic pattern and severity of valve dysfunction in children with rheumatic heart disease seen at Uganda Heart Institute, Mulago hospital. *Afr Health Sci* 14: 617-625.
16. Zühlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, et al. (2014) Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: The Global Rheumatic Heart Disease Registry (The REMEDY study). *Eur Heart J* 36: 1115-1122.
17. Malede T, Haileamlak A (2006) Pattern of heart disease in children over five years period in jimma university hospital: A retrospective study. *Ethiop J Health Sci* 16:37-46.
18. Saleh HK (2007) Pattern of rheumatic heart disease in Southern Yemen. *Saudi Med J* 28: 108-113.